Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20704047 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| SCHEMBL38953 | 0.97 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| Ammonia Solution, Strong SCHEMBL27484151 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| Iodide SCHEMBL11830139 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| Water SCHEMBL7733637 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| Water SCHEMBL4837114 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| SCHEMBL29829697 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| SCHEMBL10892597 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| Ethylene SCHEMBL6311271 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 | |
| Hydrochloric Acid SCHEMBL1572556 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KDM4ELMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| CN-101775057-A | Method for preparing drospirenone and intermediate thereof | ZHEJIANG XIANJU PHARMACEUTICAL | 2010-07-14 | — | — | CN | claimed |
| JP-56025185-A | — | — | None | — | — | JP | disclosed |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102759-A1 | POLYCRYSTALLINE-IRON-LOADED POROUS BIOCHAR AEROGEL CATALYST AND PREPARATION METHOD AND APPLICATION THEREOF | UNIV WENZHOU (CN) | 2026-04-16 | — | — | US | disclosed |
| EP-4635513-A1 | NEAR-INFRARED PHOTOSENSITIZER THAT CAN BE ACTIVATED IN SLIGHTLY ACIDIC TUMOR ENVIRONMENT AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen University (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| US-11737481-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11465985-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-10-11 | — | — | US | disclosed |
| US-4500663-A | Light stabilizing N,N,N-tris(2,2,6,6-tetramethyl-4-piperidone ketal)-1,3,5-triazine derivatives and light stabilized synthetic resin compositions | ADEKA ARGUS CHEMICAL CO., LTD. (JP) | 1985-02-19 | — | — | US | disclosed |
| EP-0095571-A2 | Polyhydric alcohol ethers of 2,2,6,6-tetramethyl-4-piperidone ketals and synthetic resin compositions | ADEKA ARGUS CHEMICAL CO., Ltd. (JP) | 1983-12-07 | — | — | EP | disclosed |
| US-4351915-A | OXIDATION AND HEAT RESISTANCE | ADEKA ARGUS CHEMICAL CO., LTD. (JP) | 1982-09-28 | — | — | US | disclosed |
| US-4323684-A | IN A POLAR SOLVENT | ADEKA ARGUS CHEMICAL CO., LTD. | 1982-04-06 | — | — | US | disclosed |
| EP-0045358-A2 | 2,2,6,6-Tetramethyl-4-piperidyl spiro aliphatic ethers as stabilizers for synthetic polymers | ADEKA ARGUS CHEMICAL CO., Ltd. (JP) | 1982-02-10 | — | — | EP | disclosed |
| JP-S5625185-A | PREPARATION OF 4-PIPERIDONE SPIROKETAL COMPOUND | ADEKA ARGUS CHEM CO LTD | 1981-03-10 | — | — | JP | disclosed |
| US-4251435-A | FOR POLYOLEFINS | THE B. F. GOODRICH COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
| US-4250313-A | HEATING A 2,2,6,6-TETRAMETHYL-4-PIPERIDONE AND A 5-METHYLOL-1,3-DIOXANE | ARGUS CHEMICAL CORP. (US) | 1981-02-10 | — | — | US | disclosed |
| US-4173599-A | 2,2,6,6-Tetraalkyl-4-piperidyl ketones and ketals as stabilizers for synthetic polymers | ARGUS CHEMICAL CORPORATION (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | SMN1; SMN2 2940/4885ALDH1A1 3574/4885KDM4E 1638/4885 |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | SMN1; SMN2 4759/4885ALDH1A1 3677/4885KDM4E 4464/4885 |
| US-20260102759-A1 | POLYCRYSTALLINE-IRON-LOADED POROUS BIOCHAR AEROGEL CATALYST AND PREPARATION METHOD AND APPLICATION THEREOF | FECH, SCO2, TFRC | SMN1; SMN2 4408/4885ALDH1A1 4239/4885KDM4E 2654/4885 |
| US-11465985-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | SMN1; SMN2 4752/4885ALDH1A1 3381/4885KDM4E 4286/4885 |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | SMN1; SMN2 4759/4885ALDH1A1 3677/4885KDM4E 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.